Q-omics provides the consensus-scored MIR548AG2 profile across patient tissues and cancer cell-line models. MIR548AG2 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR548AG2 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR548AG2 RNA expression shows 7,648 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight COAD, and KIRC as cancer lineages where MIR548AG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AG2 survival associations across molecular data types. MIR548AG2 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AG2 RNA expression–survival associations across cancer types. High MIR548AG2 expression shows unfavorable associations in COAD, OV, CHOL, KICH, PCPG and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR548AG2 RNA expression.
This table summarizes MIR548AG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AG2 shows lower tumor expression in KIRC and higher tumor expression in KICH. The KIRC box plot shows higher MIR548AG2 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with MIR548AG2 in patient tissues and cancer cell lines. In patient samples, MIR548AG2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
